ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rabies vaccine, wistar pm/wi 38-1503-3m 2.5 [iu] - suspension for injection - 2.5 iu - active: rabies vaccine, wistar pm/wi 38-1503-3m 2.5 [iu] excipient: albumin neomycin sulfate water for injection - post exposure immunisation against rabies. pre-exposure immunisation in persons at special risk of contracting rabies.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rabies vaccine, wistar pm/wi 38-1503-3m 3.25 [iu] (target quantity per dose) - powder for injection with diluent - 3.25 iu - active: rabies vaccine, wistar pm/wi 38-1503-3m 3.25 [iu] (target quantity per dose) excipient: albumin hydrochloric acid bme medium - mineral salts, vitamins, amino acids including l-phenylalanine maltose sodium hydroxide sodium chloride water for injection - verorab is indicated for pre-exposure prophylaxis against rabies. verorab is indicated for post-exposure prophylaxis against rabies. verorab should be used in accordance with official local recommendations.

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

sanofi pasteur - rabies virus (inactivated) strain wistar (pm/wi 38-1503-3m) - powder and solvent for suspension for injection in pre-filled syringe - rabies, inactivated, whole virus

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - rabies vaccine - suspension for injection - 2.5 iu/ml - rabies vaccines

קנדה - אנגלית - Health Canada

sanofi pasteur limited - rabies vaccine inactivated (human diploid-cell culture) - powder for suspension - 2.5unit - rabies vaccine inactivated (human diploid-cell culture) 2.5unit - vaccines

הממלכה המאוחדת - אנגלית - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur - rabies virus inactivated - powder and solvent for suspension for injection

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabies virus, quantity: 2.5 iu - injection, powder for - excipient ingredients: albumin; neomycin - idications as at 12 july 2004: post exposure immunisation against rabies. pre-exposure immunisation in persons at special risk of contracting rabies.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

gsk vaccines gmbh - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabies virus -

סינגפור - אנגלית - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - rabies virus (wistar rabies pm/wi 38-1503-3m strain) - injection, powder, for solution - min 2.5 iu/vial